Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.

Background: It is challenging to select the most appropriate biologic treatment for patients with moderate-to-severe plaque psoriasis.Objective: To compare speed of onset and level of skin improvem...